A Personalized Cancer Vaccine Just Passed a Major Test for Melanoma
A personalized melanoma vaccine combined with KEYTRUDA cut recurrence risk in a landmark Phase 3 trial, marking the first mRNA cancer therapy to beat.
42 articles
A personalized melanoma vaccine combined with KEYTRUDA cut recurrence risk in a landmark Phase 3 trial, marking the first mRNA cancer therapy to beat.
A new cancer vaccine called PROTEXI repurposes COVID-19 immune memory to attack tumors, slowing growth and boosting survival in melanoma and breast cancer.
Blood tests could soon predict which melanoma patients benefit from immunotherapy, after researchers identified immune cell patterns linked to survival.
A single blood test could screen for multiple cancers at once, including pancreatic and ovarian, and UNC is recruiting 2,000 North Carolinians to study it.
A new immunotherapy combo cut death risk by 52% in advanced lung cancer patients who stopped responding to checkpoint inhibitors, offering a promising new.
Women with BRCA mutations or strong family history need high-risk breast cancer screening twice yearly, alternating MRI and mammogram, starting at age 30.
Your genes may predict CAR-T cell therapy success: researchers linked three key variants to toxicity risk and treatment effectiveness in 200+ lymphoma.
Harvard's COMPASS AI predicts cancer immunotherapy response with 8.5% greater accuracy, helping doctors identify which patients will truly benefit before.
A Johns Hopkins vaccine targeting KRAS mutations triggered immune responses in 90% of high-risk patients, and none developed pancreatic cancer during.
AI-powered handheld devices have screened over 33,000 women for breast and cervical cancer in rural India, reaching villages without mammography machines.
A new melanoma drug combo shows 58% better progression-free survival; here's what advanced melanoma patients should know before their next oncology visit.
New cervical cancer screening guidelines prioritize HPV testing every three years for average-risk women ages 30 to 65, reducing unnecessary procedures.
Vaginal and vulvar cancers have survival rates as low as 53%, yet no standardized screening guidelines exist to catch them early.
Prostate cancer screening talks happen in under 7% of visits, yet men who have them are twice as likely to get screened, a new study finds.
New research finds 1 in 4 prostate cancer patients show tumor growth on scans despite stable PSA levels, suggesting imaging must join PSA testing.
Engineered bacterial vesicles injected into tumors activated whole-body immune responses against melanoma, colon, and breast cancer, offering a safer.
Colorectal cancer rates in adults under 50 have risen 63% since 1988; a new blood test could screen patients as young as 18.
Scientists engineered CAR-T cells that attack both tumor cells and the immune barriers protecting them, targeting PD-L1 to dismantle cancer's defenses.
A large NHS study found a multi-cancer blood test missed its main goal, yet still caught 16% more early-stage cancers and cut emergency diagnoses by 25%.
A new colorectal cancer drug combination improved survival to 10.9 months versus 9.4, but showed no significant benefit for patients without liver.
Personalized melanoma vaccines paired with immunotherapy are pushing survival rates from below 10% to nearly 40%, but equitable access remains a critical.
Breast cancer survivors face 17% higher cancer risk, but a new study finds annual multicancer blood tests could prevent hundreds of late-stage diagnoses.
Scientists found that blocking a protein called DHHC3 in melanoma cells triggers a powerful immune attack, shrinking tumors in animal models.
Daraxonrasib targets KRAS, mutated in 90% of pancreatic cancers, offering new hope for patients who have exhausted standard treatments.
New breast cancer research shows 68% of early-stage patients may skip chemotherapy safely, while new drug combos extend metastatic survival by years.
You can get breast and cervical cancer screening without a doctor through self-referral programs, community clinics, and health departments.
New drug combination cuts prostate cancer progression risk by 52% while pre-surgery treatment boosts survival odds in breakthrough trials.
Immunotherapy for melanoma achieves 60% response rates but can cause life-threatening side effects requiring careful monitoring and specialist care.
AI cuts breast cancer wait times from weeks to an hour, helping doctors fast-track diagnosis for high-risk women using mammogram screening.
Breast cancer screening guidelines conflict on when to start mammograms, but most experts agree: average-risk women should begin at age 40, annually.
Genetic testing beyond KRAS mutations now predicts colon cancer treatment response, with BRAF and 18q markers reshaping personalized therapy decisions.
Early breast cancer detection dramatically improves survival rates: doctors reveal key warning signs and screening tests every woman should know.
Rich countries will eliminate cervical cancer by 2048, but the gap with poorer nations could widen to 40 times higher rates without urgent investment.
A personalized melanoma vaccine plus immunotherapy cut cancer recurrence risk by 49% over five years, offering durable protection against skin cancer.
Women should start breast cancer screening at 40 and can now self-collect cervical samples, making early detection more accessible than ever.
Colorectal cancer symptoms like blood in stool and bowel changes are often dismissed, but doctors say any persistent signs need immediate attention.
Prostate cancer screening may benefit colorectal cancer survivors, but prior treatments complicate PSA tests and limit treatment options.
Skipping cancer screenings is the biggest mistake you can make, say three oncologists who warn most cancers show no symptoms until advanced.
PSA screening raises the odds of early-stage prostate cancer diagnosis by 52%, a new real-world analysis of nearly 8,000 patients shows.
Only 51% of Americans get annual cancer screenings, but 73% schedule them after learning early detection benefits could save their lives.
New colorectal cancer screening guidelines add blood tests and at-home stool options, giving the 1 in 3 unscreened adults more ways to get tested.
Researchers unveil combination therapies and engineered cell treatments to overcome melanoma immunotherapy resistance affecting many patients.